Breakthrough T1D Launches First Global Congress to Accelerate Type 1 Diabetes Cures

  • Breakthrough T1D (formerly JDRF) hosts inaugural Clinical & Research Congress in Philadelphia from October 9–11, 2026.
  • Event gathers 80+ scientific sessions with 16+ countries and dozens of global institutions represented.
  • Key focus areas include AI, immune therapies, endocrinologist shortages, and disease-modifying treatments.
  • Co-chairs include Dr. Thomas Danne, Dr. Sanjoy Dutta, and Dr. Anastasia Albanese-O'Neill.

Breakthrough T1D's inaugural congress marks a strategic pivot toward a more collaborative, interdisciplinary approach to T1D research. As the organization transitions from JDRF, this event underscores its commitment to bridging the gap between scientific discovery and real-world patient care. The focus on emerging technologies and disease-modifying therapies reflects broader industry trends toward precision medicine and digital health solutions.

Technological Integration
How AI and digital twin technologies will accelerate T1D research and treatment personalization.
Regulatory Pathways
Whether the pace of clinical trials and approvals can match the rapid advancements in T1D therapies.
Access and Equity
The extent to which breakthroughs in T1D care will be accessible to all patient populations globally.